Detalhe da pesquisa
1.
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Br J Dermatol
; 188(2): 198-207, 2023 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36763857
2.
Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two Phase 3 studies.
Clin Exp Dermatol
; 2023 Oct 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37820029
3.
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Br J Dermatol
; 186(6): 942-954, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34981829
4.
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
J Am Acad Dermatol
; 76(1): 70-80, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27707593
5.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
J Am Acad Dermatol
; 76(1): 60-69.e9, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27663079
6.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
J Am Acad Dermatol
; 73(3): 400-9, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-26092291
7.
Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on Control.
Clin Pharmacol Ther
; 111(3): 697-704, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34939180
8.
Conjugate heat transfer study of various cooling structures and sensitivity analysis of overall cooling effectiveness.
Sci Rep
; 12(1): 19271, 2022 Nov 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36357541
9.
Area level deprivation and drinking patterns among adolescents.
Health Place
; 19: 53-8, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-23178329